Viral Vector Services
Vectors that go from 0-QP release in 6 months
A lentiviral and retroviral CDMO powered by innovation
We specialize in bringing therapeutic programs to life by translating lentiviral and retroviral-based therapies from idea to reality.
Our Innovation Research team is developing next-generation vector platforms to support industry evolution, ensuring we remain at the forefront of lentiviral vector science.
Team ViroCell leverages decades of viral vector research and clinical outcome analysis to develop robust vector design strategies that de-risk your program. We consider productive titers and clinical objectives from the start.
High-yield platform process developed by team of deeply committed scientists with unparalleled technical expertise, with 20+ years of experience and ~200 GMP batches manufactured.
Agile and cost-efficient GMP manufacturing services meet critical early phase needs, high titer, rapid delivery (6 months from plasmid to GMP batch release), and phase appropriate quality.
Our viral vector services
“We’ve designed a plug-and-play approach so that we can deliver a vector to clients within six months of starting their manufacturing campaign.”